Arbutus Biopharma Corp
imdusiran
chronic hepatitis B
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for imdusiran in chronic hepatitis B are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Clinical data generated thus far has shown imdusiran to be generally safe and well-tolerated, while also providing meaningful reductions in HBsAg and HBV DNA.”